[Translation] A single-center, randomized, open-label, two-dose, two-cycle, two-sequence, single-dose, self-crossover bioequivalence study of voriconazole for injection in healthy volunteers under fasting conditions

健康志愿者在空腹状态下，单次静脉输注浙江创新生物有限公司研制的受试制剂注射用伏立康唑，与PF Prism CV持证的参比制剂注射用伏立康唑（商品名：VFEND®），比较两制剂的药代动力学特征，评价两制剂的人体生物等效性，同时评估受试制剂注射用伏立康唑和参比制剂注射用伏立康唑（VFEND®）空腹单次静脉滴注4mg/kg在中国成年健康志愿者中的安全性。

[Translation]

Healthy volunteers were given a single intravenous infusion of the test preparation of voriconazole for injection developed by Zhejiang Innovation Biotechnology Co., Ltd. under fasting conditions, and the pharmacokinetic characteristics of the two preparations were compared with the reference preparation of voriconazole for injection (trade name: VFEND®) certified by PF Prism CV. The human bioequivalence of the two preparations was evaluated, and the safety of a single intravenous infusion of 4 mg/kg of the test preparation of voriconazole for injection and the reference preparation of voriconazole for injection (VFEND®) under fasting conditions in healthy adult volunteers in China was evaluated.

Start Date12 Apr 2025

Sponsor / Collaborator

Novus Pharmaceuticals

CTR20222247

/ Active, not recruitingPhase 1

评价重组人源化抗HER2单抗-AS269偶联物(ARX788)联合特瑞普利单抗在HER2表达或突变晚期实体瘤患者中有效性及安全性的I期临床研究

[Translation] A phase I clinical study to evaluate the efficacy and safety of recombinant humanized anti-HER2 monoclonal antibody-AS269 conjugate (ARX788) combined with toripalimab in patients with advanced solid tumors expressing or mutated HER2

主要目的：Ⅰa期：评估ARX788联合特瑞普利单抗治疗HER2表达或突变晚期实体瘤患者的安全性和耐受性，确定Ⅱ期推荐剂量(RP2D)；Ⅰb期：评估ARX788联合特瑞普利单抗治疗HER2表达或突变晚期实体瘤患者的有效性，包括客观缓解率(ORR)、无进展生存期(PFS)、总生存期(OS)、疾病控制率(DCR)，缓解持续时间(DOR)。次要目的：Ia期：1) 评估ARX788联合特瑞普利单抗治疗在HER2表达或突变晚期实体瘤患者的有效性，包括客观缓解率(ORR)、无进展生存期(PFS)、总生存期(OS)、疾病控制率(DCR)，缓解持续时间(DOR)；2）评价ARX788联合特瑞普利单抗在HER2表达或突变晚期实体瘤患者中的药物代谢动力学(PK)特征；3）评价ARX788联合特瑞普利单抗在HER2表达或突变晚期实体瘤患者中ARX788的免疫原性。Ib期：1）评估ARX788联合特瑞普利单抗治疗HER2表达或突变晚期实体瘤患者的安全性和耐受性；2）评价ARX788联合特瑞普利单抗在HER2表达或突变晚期实体瘤患者中ARX788的免疫原性。

[Translation]

Main purpose: Phase Ia: To evaluate the safety and tolerability of ARX788 combined with toripalimab in the treatment of patients with advanced solid tumors expressing or mutated HER2, and determine the recommended dose (RP2D) for Phase II; Phase Ib: To evaluate the effectiveness of ARX788 combined with toripalimab in the treatment of patients with advanced solid tumors expressing or mutated HER2, including objective response rate (ORR), progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and duration of response (DOR). Secondary objectives: Phase Ia: 1) Evaluate the effectiveness of ARX788 combined with toripalimab in patients with advanced solid tumors expressing or mutated HER2, including objective response rate (ORR), progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and duration of response (DOR); 2) Evaluate the pharmacokinetic (PK) characteristics of ARX788 combined with toripalimab in patients with advanced solid tumors expressing or mutated HER2; 3) Evaluate the immunogenicity of ARX788 combined with toripalimab in patients with advanced solid tumors expressing or mutated HER2. Phase Ib: 1) Evaluate the safety and tolerability of ARX788 combined with toripalimab in patients with advanced solid tumors expressing or mutated HER2; 2) Evaluate the immunogenicity of ARX788 combined with toripalimab in patients with advanced solid tumors expressing or mutated HER2.

Start Date04 Nov 2022

Sponsor / Collaborator

NovoCodex Biopharmaceuticals Co., Ltd.

CTR20222161

/ RecruitingPhase 1

评价注射用重组人源化抗CD70单抗-AS269偶联物（ARX305）在晚期肿瘤患者中的安全性、耐受性、药代动力学特征及初步有效性的开放、多中心、I期临床研究

[Translation] An open, multicenter, phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of recombinant humanized anti-CD70 monoclonal antibody-AS269 conjugate (ARX305) for injection in patients with advanced tumors

主要目的：评价ARX305的安全性和耐受性；确定ARX305的最大耐受剂量（MTD）和Ⅱ期研究的推荐剂量（PR2D）。次要目的：评价ARX305及其代谢产物的药代动力学特征；评价ARX305的初步抗肿瘤疗效；评估ARX305的免疫原性；评估CD70表达与ARX305疗效相关性。

[Translation]

Primary objectives: To evaluate the safety and tolerability of ARX305; to determine the maximum tolerated dose (MTD) of ARX305 and the recommended dose (PR2D) for phase II studies. Secondary objectives: To evaluate the pharmacokinetic characteristics of ARX305 and its metabolites; to evaluate the preliminary anti-tumor efficacy of ARX305; to evaluate the immunogenicity of ARX305; and to evaluate the correlation between CD70 expression and the efficacy of ARX305.

Start Date19 Oct 2022

Sponsor / Collaborator

NovoCodex Biopharmaceuticals Co., Ltd.

100 Clinical Results associated with Zhejiang Medicine Co., Ltd.

0 Patents (Medical) associated with Zhejiang Medicine Co., Ltd.

220

Literatures (Medical) associated with Zhejiang Medicine Co., Ltd.

14 Jul 2025·CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION

The effect of probiotics supplementation on cancer-treatment complications: a critical umbrella review of interventional meta-analyses

Review

Author: Zarezadeh, Meysam ; Liang, Youfeng ; Yao, Keying ; Yang, Zhao ; Jamilian, Parmida ; Wang, Jianfeng ; Zhang, Shijie ; Chen, Ruolan ; Yu, Changyuan ; Li, Chunhui ; Kord-Varkaneh, Hamed ; Chen, Xiaoyang ; Zhang, Wenjing ; Li, Hanmin ; Ying, Lu

Cancer-related complications pose significant challenges in the management and treatment of patients with malignancies. Several meta-analyses have indicated improving effects of probiotics on cancer complications, while some studies have reported contentious findings. The purpose of the present study was to evaluate the efficacy of probiotics in addressing cancer complications, including diarrhea, mucositis, and infections, following chemotherapy, radiotherapy, and surgery. Relevant studies were searched in the PubMed, Scopus, Embase and Web of Science databases and Google Scholar up to September 2023. All meta-analyses addressing the effects of probiotics on all cancer treatments-induced complications including infection, diarrhea and oral mucositis were included. The pooled results were calculated using a random-effects model. Analyses of subgroups, sensitivity and publication bias were also conducted. The results revealed that the probiotics supplementation was effective on reduction of total cancer complications (OR:0.53; 95% CI: 0.44, 0.62, p < 0.001; I²=79.0%, p < 0.001), total infection rate (OR:0.47; 95%CI: 0.41, 0.52, p < 0.001; I²= 48.8%, p < 0.001); diarrhea (OR:0.50; 95%CI: 0.44, 0.57, p < 0.001; I²=44.4%, p = 0.023) and severe diarrhea (OR: 0.4; 95%CI: 0.27, 0.56, p < 0.001; I²=31.3%, p = 0.178), oral mucositis (OR: 0.76; 95%CI: 0.58, 0.94, p < 0.001; I²=95.5%, p < 0.001) and severe oral mucositis (OR:0.65, 95%CI: 0.58, 0.72 p < 0.001; I²=22.1%, p = 0.274). Multi strain probiotic (OR:0.49; 95%CI: 0.32, 0.65, p < 0.001; I²=90.7%, p < 0.001) were more efficacious than single strain (OR:0.73; 95%CI: 0.66, 0.81, p < 0.001; I²=0.00%, p = 0.786). The findings of the current umbrella meta-analysis provide strong evidence that probiotic supplementation can reduce cancer complications.

01 Jul 2025·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Multifunctional sesquiterpene synthase from Curcuma wenyujin reveals the biosynthetic mechanism of sesquiterpenes with diverse skeletons

Article

Author: Wei, Qiuhui ; Li, Dengyu ; Ma, Jing ; Hu, Tianyuan ; Xia, Yimeng ; Zhang, Qin ; Zhang, Yifeng ; Hu, Yuhan ; Zhou, Jiawei ; Fang, Gaowei ; Xu, Mengdie ; Ma, Xiaoxia ; Yin, Xiaopu

Volatile sesquiterpenes derived from Curcuma wenyujin Y.H.Chen et C. Ling exhibit potent pharmacological activities but remain underexplored in terms of their biosynthesis. In this study, a multifunctional sesquiterpene synthase, CwTPS5, was identified from C. wenyujin, which can utilize farnesyl diphosphate (FPP) as a substrate to produce five distinct categories of sesquiterpenes based on their structural skeletons, resulting in at least 17 different sesquiterpene compounds, including previously unreported humulane-and spirane-type compounds in C. wenyujin. Many of its products serve as important active components or precursors of other bioactive sesquiterpenes found in volatile oils. Additionally, molecular docking-guided mutagenesis identified several key amino acids that regulate the product diversity of CwTPS5. Notably, the R456E and C404S mutations shifted product dominance from selinenes (81.4 %) to germacrene A (72.2 %) and hedycaryol (83.4 %), respectively. Overall, these findings provide valuable insights into the biosynthesis of sesquiterpenes in C. wenyujin and offer potential approaches for the production of these bioactive sesquiterpenes through metabolic engineering.

01 May 2025·FOOD CHEMISTRY

Interaction of major tea polyphenols with bovine milk proteins and its effect on in vitro bioaccessibility of tea polyphenols

Article

Author: Lu, Baiyi ; Tao, Fei ; Jia, Zhenbao ; Peng, Jiyu ; Chen, Xiachao ; Zhou, Fei

Adding bovine milk into tea and tea-containing beverages has been popular nowadays, while this dietary system may affect the digestion and absorption of tea polyphenols. In this work, the interactions of tea polyphenols with bovine milk proteins and their impacts on the bioaccessibility of tea polyphenols were investigated. The results indicate that tea polyphenols interact with amino acid residues of bovine milk proteins through hydrogen bonds and van der Waals forces spontaneously. Tea polyphenols cause static fluorescence quenching of bovine milk proteins, with different interaction types through one binding site. The interaction between tea polyphenols and bovine milk proteins forms a complex, which reduces the contents of α-helix, β-turn, and random coil in the secondary structure of bovine milk proteins while increasing the β-sheet content. Tea polyphenol-bovine milk protein interaction can enhance the bioaccessibility of tea polyphenols, with esterified tea polyphenols epicatechin gallate and epigallocatechin gallate showing better improvement effects.

News (Medical) associated with Zhejiang Medicine Co., Ltd.

17 Feb 2025

·www.echemi.com

Over 257 Biopharma Companies Project Record Profit Growth in 2024

As of February 13, a total of 257 biopharmaceutical companies have disclosed their performance forecasts for 2024, with over 50 firms expecting to see their net profits double. Notably, companies such as North China Pharmaceutical, Zhejiang Medicine, Darentang, Huilong Pharmaceutical, and Sanofi are among those predicting substantial increases. Among these, North China Pharmaceutical anticipates that its net profit attributable to shareholders will reach approximately 125 million yuan, reflecting a staggering 2456.08% year-on-year growth. The company attributes this remarkable performance to strategic adjustments in product structure, enhanced procurement management, and effective cost control measures. Hehua Co. is also forecasting impressive results, with expected revenues between 190 million and 250 million yuan and a net profit of 78 million to 86 million yuan, marking a 774.79% to 844% increase. The firm has benefited from transferring its urea production capacity, resulting in significant non-operating income. Microelectrophysiology projects a net profit between 47 million and 56 million yuan, indicating a remarkable increase of 726.23% to 884.44%. The company’s growth stems from enhanced market strategies and the successful expansion of its high-value product lines, including the TrueForce® pressure monitoring catheter. Haizheng Pharmaceutical estimates a net profit in the range of 570 million to 630 million yuan, reflecting a 711.78% to 776.17% increase, driven by strong product growth and operational efficiencies. These figures underscore the evolving landscape of the biopharmaceutical industry, as companies adapt and thrive amid changing market conditions. With innovative strategies and products, these firms are well-positioned for a prosperous year ahead.

Financial StatementBiosimilar

22 Oct 2023

·www.fiercebiotech.com

ESMO: Ambrx's 'reset' arrives at the last line of prostate cancer, offering the kind of safety rarely seen

Almost a year to the day before Ambrx's ESMO presentation, the company laid off 15% of its staff and trimmed the pipeline down to ARX517 and a couple other early-stage assets. MADRID—When patients reached Ambrx Biopharma’s phase 1/2 clinical trial for prostate cancer, they were nearing the end of their treatment journey. It’s hard to read that some had gone through 13 rounds of treatment before they entered the study. CEO Daniel O’Connor and Chief Clinical Officer Sandra Aung don’t take that lightly. “They're last line patients, they have no other options and typically patients in that bucket go for clinical trials,” Aung said on the sidelines of the European Society for Medical Oncology Congress in Madrid. Ambrx wants to provide another option, but more importantly, a better option for these patients who are facing difficult decisions after a long fight with cancer. The company unveiled early-stage data from the APEX-01 study of the antibody-drug conjugate (ADC) ARX517 showing anti-cancer activity and few adverse events—none serious. For efficacy, Ambrx reported that more than half of the 23 patients had a 50% or more reduction in prostate specific antigen, which is elevated in prostate cancer. Seventeen out of 21, or 81% of evaluable patients, also had a steep reduction in circulating tumor DNA. In a smaller analysis of six patients, half who had prior prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy, had more or equal to 50% reduction in prostate specific antigen. And out of four evaluable patients, half had a 30% or more reduction in target lesions. There were no treatment-related serious adverse events or dose limiting toxicities, a discontinuation rate of just 3.1% and fewer than 10% grade 3 treatment related adverse events—but no grade 4 or 5s. Aung said the safety data are particularly important for these late-stage patients: “We don’t want to make them sicker.” “I don't know if I've ever seen a late-stage cancer drug, after two years of clinical development, not having an [serious adverse event]. Not one,” O’Connor said in an interview. The grade 3 events were lymphocyte count decreases, platelet count decreases and one instance of left ventricular dysfunction, which Aung said was found in the course of the treatment and was not considered serious. “We don't want to diminish what a grade 3 is, but on a grand scheme of things for this late-line patient on this drug, [it’s] very tolerable. We would feel very comfortable calling it strong safety,” Aung said. While the data are from a small population, Ambrx is already forming a detailed strategy of next steps. Aung said that the safety profile resulted from the biotech’s careful testing and drug discovery process. “It's very rare to find this kind of safety profile. It is really born from technology, it's not luck,” she said. There’s still a lot to do in the clinic, including fully enrolling the study and conducting dose expansion, O’Connor said. With so few safety events, he thinks the dose can go higher to push efficacy even further. “Ultimately, if we see a data plateau and we see an impact over efficacy, we'll make a decision probably not to move forward to a higher level,” O’Connor said. “It's incumbent on us to continue to explore higher doses to see if there's more efficacy.” Ambrx also saw in the small dataset the possibility that the treatment will work regardless of a patient’s PSMA biomarker levels, which would mean ARX517 could have access to a wide patient population. The trial did not screen for PSMA, so the patients had a mix of high and low levels. “If we don't have to have a biomarker program, we do not want to have one,” O’Connor said. Aung said they are certainly going to collect that data, but the goal is not to pick one population over the other. “We want to be able to treat patients, not have to select them,” she added. “We're going to collect it and we're going to look at the data and make a decision on whether it's necessary or not.” Ambrx's scorecard The ESMO presentation represents a major reset for Ambrx. Almost a year to the day, the biotech laid off 15% of its staff and trimmed the pipeline down to ARX517 and a couple other early-stage assets. The dramatic moves came after a breast cancer program fell apart. “Focus is really the key for us. And I think frankly, we’re really pleased with the progress the company has made this year,” said O’Connor, who took the helm in November 2022 after the layoffs. “There was a reduction that happened last fall. A year later, there's really kind of a complete change. A reset.” Aung is another fresh face, having taken on her role in February. Ambrx has also managed to raise some cash and extend its runway to 2026, all in a market O’Connor admits is challenging for the larger industry. The most recent offering in June closed with $75 million, which followed a $78 million raise in March. Even the breast cancer program, initially the cause of the company cutbacks, is returning. In March, Ambrx said that a phase 2 study in China conducted by partner NovoCodex Biopharmaceuticals showed that ARX788 demonstrated better progression-free survival than the control group. O’Connor moved to resurrect the drug. “It was shelved not because of efficacy, it was shelved because the company was concerned about cash burn a year ago, just before I was the CEO,” O’Connor said. Ambrx always believed there was a signal in the data. Now, he says Ambrx is conducting a small signal-finding study in a group of breast cancer patients who have no other options. The FDA had previously granted a fast-track tag for the treatment. “On each scorecard, we feel like we've really changed the trajectory of the company. And we are really pleased with the progress,” O’Connor said.

Phase 2ADC

16 Jun 2023

·www.prnewswire.com

Global Natural Source Vitamin E (Tocopherols and Tocotrienols) Market: Demand for Natural Vitamin E is Projected to Reach About 20K Metric Tons by 2028

DUBLIN, June 16, 2023 /PRNewswire/ -- The "Natural Source Vitamin E (Tocopherols and Tocotrienols) - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering. Global demand for Natural Source Vitamin E reached US$1.1 billion in 2022, registering a YOY growth of 17% attributed to huge price increase in Tocopherols. Dietary Supplements sector is the largest consumer of Natural Vitamin E worldwide and any upturns and downturns in the demand from Dietary Supplements will directly reflect in the overall Natural Vitamin E market. Amid the pandemic induced upturn in the demand for supplements and fortified foods & beverages, the global Natural Vitamin E consumption has significantly increased during 2020-2021 period. Demand growth for supplements and fortified foods slowed down likewise significantly in 2022 as the threat by the pandemic continued to wane and the global economic conditions weakened. Rising energy costs, supply chain disruptions and tight supply of vegetable oil distillates has prompted Tocopherols producers to increase prices during the 2021-2022 period. As evident from the industry, vitamin E prices are expected to remain stable at 2022 levels during the forecast period (2022-2028) as the global supply chain conditions are improved and energy costs are coming down. In light of high inflation and rising Tocopherols prices, consumers are likely to become increasingly price sensitive heading into the forecast period, and the global volume consumption of Natural Vitamin E is projected to progress at a moderate CAGR of 3.6% between 2022 and 2025. As economic conditions are expected to back to normal after 2025, the global demand for Natural Vitamin E is projected to reach about 20K metric tons by 2028. Research Findings & Coverage Global Natural Source Vitamin E market is analyzed in this report with respect to key product types and major end-use sectors The study exclusively analyzes the market size of each product type and end-use sectors of Vitamin E by a major geographic region/country The market for Natural Vitamin E Tocopherols and Natural Vitamin E Tocotrienols is analyzed by end-use applications individually for all major regions/countries Analysis of Market Drivers, Restraints and Opportunities In-depth analysis is covered for global Natural Vitamin E market with respect to rising prices and inflation while the study also takes the recent pandemic impact in to consideration Production capacity shares of all major Tocopherols and Tocotrienols producers are analyzed Key business trends focusing on product innovations/developments, M&As, JVs and other recent industry developments Major companies profiled - 43 The industry guide includes the contact details for 223 companies Product Outline The report analyzes the market for the following key product types of Natural Vitamin E: Tocopherols Tocotrienols End-Use sectors of Natural Vitamin E analyzed comprise the following: Animal Nutrition/Feed Dietary Supplements Food and Beverages Cosmetics & Personal Care Others (include pharmaceuticals, medical nutrition, and infant nutrition) Analysis Period, Units and Growth Rates The report reviews, analyzes and projects the global Natural Vitamin E market for the period 2019-2028 in terms of volumes in Metric Tons and market value in US$ and the compound annual growth rates (CAGRs) projected from 2022 through 2028 with a special focus on y-o-y growth analysis for 2021-2022 Geographic Coverage North America (The United States, Canada and Mexico) Europe (Germany, France, Italy, Spain, The Netherlands, The United Kingdom and Rest of World) Asia-Pacific (China, India, Japan and Rest of Asia-Pacific) South America (Brazil, Argentina and Rest of South America) Rest of World Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 1.1 Market Trends and Outlook 1.2 Overall Vitamin E Market At-a-Glance 1.3 Product Outline 1.3.1 What is Vitamin E? 1.3.2 Forms of Vitamin E 1.3.2.1 Synthetic Vitamin E 1.3.2.2 Natural Source Vitamin E 1.3.2.2.1 Tocopherols 1.3.2.2.2 Tocotrienols 1.3.2.2.3 Vitamin E TPGS (d-Alpha Tocopheryl Polyethylene Glycol 1000 Succinate) 1.3.3 Manufacturing Processes of Vitamin E 1.3.3.1 Synthetic Vitamin E 1.3.3.2 Natural Source Vitamin E 1.3.3.2.1 Tocopherols 1.3.3.2.2 Tocotrienols 1.3.4 Sources of Vitamin E 1.3.4.1 Food Sources 1.3.4.2 Dietary Supplements 1.3.5 Vitamin E Health Claims 1.3.5.1 Coronary Heart Disease 1.3.5.2 Cancer 1.3.5.3 Disorders of the Eyes 1.3.5.4 Cognitive Decline 1.3.5.5 Other Health Claims 1.3.6 End-Use Applications of Vitamin E 1.3.6.1 Animal Nutrition 1.3.6.2 Human Nutritional/Dietary Supplements 1.3.6.3 Functional Food and Beverages 1.3.6.4 Cosmetics 1.3.6.5 Other Applications 2. REGULATIONS FOR DIETARY SUPPLEMENTS AND INGREDIENTS 2.1 Ministry of Health Malaysia Approves Two Health Claims for Palm Tocotrienols 2.2 Regulations for Dietary Supplements and Ingredients as per the US Food and Drug Administration (FDA) 2.2.1 How the Safety of Dietary Supplements is Ensured 2.2.2 Registration of Food Facilities 2.2.3 Notification Process for New Dietary Ingredients 2.3 FDA Changes Nutrition Facts Label on Food Packaging 2.3.1 FDA Guidance for Industry on Converting Units of Measure for Vitamin E 2.4 European Union: Traceability and Labeling of GMOs 3. INDUSTRY LANDSCAPE 3.1 Global Vitamin E Production Capacities 3.1.1 Global Natural Vitamin E Tocopherols Capacity 3.1.2 Global Natural Vitamin E Tocotrienols Capacity 3.2 Natural Vitamin E Tocopherols Manufacturers Advanced Organic Materials S.A. (Argentina) Archer Daniels Midland Company (United States) BTSA Biotecnologias Aplicadas Sl (Spain) COFCO Tech Bioengineering (Tianjin) Co., Ltd. (China) DSM Nutritional Products (Royal DSM NV) (Netherlands) Cargill, Inc (United States) ECA Healthcare Inc. (China) Fairchem Organics Limited (India) Fenchem Biotek Ltd. (China) Fujian Fuerjin Biotechnology Co., Ltd. (China) Fujian Glanny Bio-Engineering Co., Ltd. (China) Jiangsu Conat Biological Products Co., Ltd. (China) Jiangsu Xixin Vitamin Co., Ltd. (China) Jiangsu Yuehong Bio-Tec Co., Ltd. (China) Jiangxi Aturex Co Ltd (China) J-Oil Mills, Inc. (Japan) Kensing, LLC. (United States) Vitae Naturals (Spain) Matrix Life Science Pvt. Ltd. (India) Mitsubishi-Chemical Foods Corporation (Japan) Tama Biochemical Co., Ltd. (Japan) Ningbo Dahongying Bio-Engineering Co., Ltd. (China) Riken Vitamin Co., Ltd. (Japan) Shandong New Element Biotechnology Co., Ltd. (China) Vitae Naturals (Vitae Caps, S.A.) (Spain) Wilmar Spring Fruit Nutrition Products (Jiangsu) Co., Ltd. (China) Xi'an Healthful Biotechnology Co Ltd (HSF) (China) Yichun Dahaigui Life Science Co., Ltd. (China) Zhejiang Medicine Co., Ltd. (China) Zhejiang Worldbestve Biotechnology Co., Ltd. (China) 3.3 Natural Vitamin E Tocotrienols Manufacturers American River Nutrition, Inc. (United States) Beijing Gingko Group (China) ExcelVite Sdn. Bhd. (Malaysia) KLK Oleo (Davos Life Science) (Singapore) Musim Mas Group (Singapore) Oryza Oil & Fat Chemical Co., Ltd. (Japan) Pwani Oil Products Limited (Kenya) ORAH Nutrichem Exim Pvt. Ltd. (India) Phytogaia Sdn. Bhd. (Malaysia) Sime Darby Oils Nutrition (Malaysia) SOP Nutraceuticals Sdn. Bhd. (Malaysia) Supervitamins Sdn. Bhd. (Malaysia) Vance Group Ltd. (Singapore) 4. KEY BUSINESS TRENDS Kensing Acquires Spain-based Natural Vitamin E Producer Vitae Naturals ORAH Nutrichem Introduces ORAH VIT E Tocotrienol based Natural Antioxidant Kensing Inks Distribution Deal with Azelis in the EMEA Region One Rock Capital Partners Acquires BASF's Kankakee, Illinois Natural Vitamin E Plant Antares Introduces Pharmaceutical and Food Grade Non-GMO Sunflower TPGS 5. GLOBAL MARKET OVERVIEW 5.1 Global Natural Vitamin E Market Overview by End-Use Application 5.2 Global Natural Vitamin E Market Overview by Type 5.2.1 Natural Vitamin E - Tocopherols 5.2.1.1 Global Natural Vitamin E Tocopherols Market Overview by End-Use Application 5.2.2 Natural Vitamin E - Tocotrienols 5.2.2.1 Global Natural Vitamin E Tocotrienols Market Overview by End-Use Application PART B: REGIONAL MARKET PERSPECTIVE Natural Vitamin E Market Overview by Geographic Region Global Natural Vitamin E Tocopherols Market Overview by Geographic Region Global Natural Vitamin E Tocotrienols Market Overview by Geographic Region REGIONAL MARKET OVERVIEW 6. NORTH AMERICA 7. EUROPE 8. ASIA-PACIFIC 9. SOUTH AMERICA 10. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. Major Manufacturers and Suppliers of Vitamin E Manufacturers of Natural Vitamin E Tocopherols Manufacturers of Natural Vitamin E Tocotrienols Vitamins and Other Ingredients Distributors 2. Major Companies in the End-use Application Industries for Vitamin E Nutritional Supplements Companies Direct Selling Companies - Supplements and Personal Care Contract Manufacturers - Supplements Animal Feed/Nutrition Companies Vitamins and Other Ingredients Distributors and Formulators PART D: ANNEXURE 1. RESEARCH METHODOLOGY 2. FEEDBACK For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

100 Deals associated with Zhejiang Medicine Co., Ltd.

100 Translational Medicine associated with Zhejiang Medicine Co., Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 20 Jul 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

IND Approval

Phase 1

Phase 2

Phase 3

Approved

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Vancomycin Hydrochloride ( Peptidoglycan )	Bone and joint infections More	Approved
Bedoradrine Sulfate ( β2-adrenergic receptor )	Asthma More	Phase 2
XCCS605B ( Chk1 )	Colonic Cancer More	Phase 1
ARX-305 ( CD70 x Tubulin )	CD70 positive Neoplasms More	Phase 1
NCB-001	Neoplasms More	Clinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis